Senescence is a powerful mechanism that prevents the development of tumors in vivo; however, once tumors are formed, most are refractory to senescence in response to oncogenic stress. Therefore, a novel pathway leading to senescence is required. We herein demonstrated that the cell cycle regulator CDC6 translocated from the nucleus to the cytoplasm during senescence in a leptomycin B-resistant manner. In order to evaluate the translocation of CDC6, we utilized an estrogen receptor (ER) tag to retain CDC6 in the cytoplasm. ERtagged CDC6 was exclusively cytoplasmic, inhibited cell proliferation, and induced senescence-associated (SA) b-galactosidase activity. Furthermore, ER-CDC6 inhibited the transformation of mouse fibroblasts by the active ras oncogene in vitro, and suppressed tumor formation in NOD-SCID mice. Thus, CDC6 may play a critical role in the regulation of senescence in the cytoplasm in order to counteract tumorigenesis. Corresponding author: Jun-ya Kato, Graduate School of Biological Sciences, Nara Institute of Science and Technology, Nara, Japan. , E-mail: jkata@bs.naist.jp (J-yK).
Introduction
Mammalian cells are equipped with mechanisms that prevent the formation and development of tumors, such as checkpoint controls, DNA damage responses, differentiation, apoptosis, and senescence. Of these, senescence has been proposed to strongly suppress the formation and development of tumors [1, 2] ; however, its mechanism of action and pathways have not yet been elucidated in detail. Senescence is characterized by eternal withdrawal from the cell cycle and was originally identified as a mechanism determining the life span of primary cells cultured in vitro; however, subsequent studies reported that it was induced under several different conditions, such as telomere shortening, DNA damage, oxidative stress, the abrupt activation of oncogenes, and the developmental program [3, 4, 5] . These findings demonstrated that senescence is a cellular response to stress that disables the proliferation of cells. Senescence has been recognized as a part of the system that prevents the tumorigenic transformation of mammalian cells [1, 2] by inhibiting cell proliferation, and eliminates damaged cells via an inflammatory process by affecting surrounding cells through secreted factors [6] .
The tumor suppressor, p53, was previously shown to play an important role in senescence and tumor suppression by triggering the expression of a series of genes involved in cell cycle arrest and the onset of senescence, such as the CDK inhibitor p21, which negatively regulates G1 cyclin-CDK complexes, ultimately leading to the dephosphorylation and activation of the Rb protein [3] . In the initial stage of tumorigenic transformation in vivo, cells are induced to undergo senescence in order to prevent transformation [7, 8, 9 ,10], and p53 has been shown to play a role in this process [11, 12] . However, when cells go through this antitumorigenic barrier, tumor cells acquire mutations in relevant genes such as those involved in the p53 pathway, and become refractory to senescence.
Although previous studies reported that a p53-independent mechanism was involved in the control of senescence [13, 14, 15, 16, 17] , and also that Rb, but not other members of the Rb family, played an essential role in senescence [18] , novel molecular switches to initiate the senescence program, which are desired to counteract tumorigenic transformation, have not yet been identified.
During the course of our research on the COP9 signalosome (CSN) complex [19, 20] , an upstream regulator of the cullin-RING ubiquitin ligase (CRL) complex, we found that gene-knockout of the fifth component of CSN (CSN5) induced premature senescence in mouse fibroblasts, even in the absence of p53 [21] . The depletion of CSN5 increased CDK2 and cyclin E levels in the cytoplasm, whereas the concomitant knockdown of CDK2 reduced cytoplasmic cyclin E levels and rescued the induction of senescence [22] . Cytoplasmic cyclin E was previously detected in mouse embryonic fibroblasts (MEFs) that entered proliferative senescence [22] . The enforced expression of cytoplasmic cyclin E in immortalized mouse and human cells has been shown to induce senescence [22] . Thus, the cytoplasmic retention of cyclin E, CDK2, and their interacting proteins was identified as a key event that induced premature senescence in a novel manner.
In the present study, we focused on the cell cycle regulator CDC6 as one of the interactors of cyclin E and CDK2 [23] . CDC6 is known to play an essential role cells, [22] , suggesting that certain cyclin E-interacting proteins are located in the cytoplasm of CSN5-knockout cells and may trigger the senescence-initiating program.
We suspected that CDC6 was one such protein and subsequently investigated this possibility. CDC6 has been shown to play an important role in the regulation of DNA replication by assisting in the assembly of the pre-replication complex (RC) at the G1 phase of the cell cycle [24] . In order to achieve this, CDC6 exerts its effects in the nucleus with the aim of associating with origin recognition complex (ORC) proteins. After the onset of the S phase, CDC6 is phosphorylated, ubiquitinated, translocated to the cytoplasm, and degraded by the proteasome to avoid re-replication [26, 27, 28] . If CDC6 plays a role in senescence and is involved in the cytoplasmic location of cyclin E, it may be located in the cytoplasm of senescent cells.
CDC6 was largely located in the nuclei of proliferating NIH3T3 cells and MEFs harboring p53 -/-alleles, which are immortal and do not enter senescence, and cytoplasmic staining was weak (Fig. 1a, b ). This result was consistent with previous findings in which the CDC6 protein exported from the nucleus in proliferating cells was unstable and rapidly degraded through the ubiquitin-proteasome system [26, 27, 28] . However, the CDC6 -specific fluorescent signal was significantly strong in the cytoplasm of CSN5-null (CSN5 -/D ) MEFs, which were generated by introducing CRE-ER into CSN5 -/floxed p53 -/-MEFs followed by a treatment with 4OHT (Fig. 1a) .
Approximately 40% of proliferating MEFs contained nuclear CDC6, whereas less than 5% of senescent MEFs showed nucleus-specific CDC6 staining (Fig. 1b) .
We utilized replicative-senescent cells to determine whether cytoplasmic CDC6 was restricted to CSN5-knockdown cells. Wild-type MEF cells were cultured in vitro, and the subcellular localization of CDC6
was compared between early (less than 5 passages) and late (more than 10 passages) passages (Fig. 1c, d ).
Proliferating pre-senescent MEF cells (early passage) exhibited similar staining patterns to NIH3T3 cells.
However, nuclear staining was not strong in late passage MEFs and the CDC6-specific fluorescent signal was significantly strong in the cytoplasm (Fig. 1c) .
Approximately 50% of proliferating MEFs contained nuclear CDC6, whereas less than 5% of senescent MEFs showed clear nuclear CDC6 staining (Fig. 1d) .
Furthermore, cytoplasmic staining of CDC6 in late passage MEFs was resistant to leptomycin B (LMB), a chemical inhibitor to nuclear export (Fig. 1c, d ), which indicated that the cytoplasmic location of CDC6 was not due to accelerated nuclear export, but rather to cytoplasmic retention.
ER-fused CDC6 was Predominantly located in the
Cytoplasm, inhibited Cell Proliferation, and Induced Senescence.
In order to explore the possible roles of cytoplasmic CDC6, CDC6 was predominantly expressed in the cytoplasm. Since cytoplasmic CDC6 in senescent cells was refractory to the effects of LMB, we enforced the cytoplasmic retention of CDC6 rather than enhancing its export from the nucleus, and fused CDC6 with an ER tag to achieve this [29] . ER is a nuclear receptor that is exclusively retained in the cytoplasm in the absence of a Figure 2b shows that HA-CDC6 was predominantly located in the nucleus, whereas HA-CDC6
-ER was largely located in the cytoplasm.
Since ER is transferred to the nucleus after ER tagging is a widely used method to control the subcellular distribution of a protein between the nucleus and cytoplasm with few side effects. For example, an ER-tagged CRE recombinase is generally used to induce conditional knockout in mice and cells containing floxed sequences in the loci of interest. We previously used the CRE-ER system to conditionally knockout the CSN5 allele without any undesirable side effects [22, 30] , and successfully applied this system to other proteins [22] . Therefore, the results obtained with ER-tagged CDC6 were attributed to the cytoplasmic localization of the CDC6 protein, but not to the expression of ER.
Taken together, although cells expressing cytoplasmic CDC6 remained alive (Fig. 4) , their proliferation was inhibited (Fig. 3) , and a senescence marker was induced (Fig. 4) . Furthermore, an increase in the amount of nuclear CDC6 did not overcome the cytoplasmic CDC6-mediated inhibition of proliferation (Fig. 3) . Therefore, we concluded that the cytoplasmic localization of CDC6 triggered the senescence-initiation 
CDC6 Bound to Cyclin E in Vitro and in Vivo.
CDC6 is a well-known substrate of CDK2 kinase [28] , and is expected to interact with cyclin E and CDK2 [23] . We confirmed the interaction between CDC6 and cyclin E using an in vitro binding assay. Recombinant
GST and GST-fused cyclin E proteins produced in bacteria were immobilized on glutathione beads and mixed with a cell lysate containing the ectopicallyexpressed HA-tagged CDC6 protein. Bound CDC6 was detected by immunoblotting using an antibody to an HA epitope. Figure 5a showed that CDC6 interacted with cyclin E in vitro.
We next determined whether cytoplasmic CDC6 
Cyclin E Translocated to the Cytoplasm in CDC6-ER-Transfected Cells.
Cyclin E was detected in the cytoplasm of CSN5-null cells that underwent senescence, and the enforced expression of cyclin E in the cytoplasm induced senescence [22] . Since CDC6 interacted with cyclin E in vitro and in vivo (Fig. 5a, b) , we investigated the intracellular localization of cyclin E in cells transfected with HA-CDC6/HA-CDC6-ER by immunofluorescent staining with a specific antibody to cyclin E. Figure 5c shows that cyclin E was exclusively located in the nucleus in some cells that were introduced with GFP and HA-CDC6. In contrast, a significant percentage of HA-CDC6-ER-transfected cells had cytoplasmic cyclin E in addition to nuclear cyclin E (Fig. 5c) . A quantitative analysis revealed that this difference was significant 
Discussion
The function of the CSN is critical to mammalian cell proliferation and tumorigenesis, and the expression of the fifth subunit was previously shown to frequently be elevated in many human cancers [20] , indicating that CSN5 possesses a specific function that is closely connected to tumor cell proliferation. We previously reported that CSN5, but not the whole CSN complex, interacted with a key regulatory element of the cell cycle, CDK2 [22] . The interaction between CSN5 and CDK2 participated in the control of premature senescence, and, in this process, CDK2 and its partner cyclin E were retained in the cytoplasm. The enforced expression of cyclin E in the cytoplasm induced senescence [22] , suggesting that cyclin E has a novel function in the cytoplasm to induce senescence. In the present study, we focused on CDC6 because it is a key molecule involved in cell cycle regulation and is also an interactor of cyclin E. We found that CDC6 was located in the CDC6 plays a key role in DNA replication and cell cycle progression; therefore, it is expected to have oncogenic properties. The CDC6 gene was previously reported to be amplified and overexpressed in human gastric cancer [31] . High levels of CDC6 have also been detected in brain tumors [32] , non-small cell lung carcinomas [33] , and mantle cell lymphomas [34] . However, the overexpression of CDC6 does not necessarily correlate with increased proliferation [33] , suggesting that CDC6 has oncogenic activities other than accelerated DNA replication. Previous studies reported that deregulated CDC6 inactivated the INK4A/ARF locus, which encodes tumor suppressor proteins that function upstream of the Rb and p53 pathways [35] , that the expression of CDC6 repressed E-cadherin transcription [36] , and also that CDC6 obstructed apoptosome assembly by binding to Apaf-1 [37] . In the present study, we showed that cytoplasmic CDC6, which was exclusively observed in senescent cells, exerted antitumorigenic activity, possibly as a result of interference with the oncogenic pathway in which nuclear CDC6
participates. Among the possible functions of CDC6 described above, p53 is known to be connected with the senescent pathway [18] ; however, the mouse fibroblast 
